PepGen receives FDA clinical hold for Phase 2 DMD trial IND

PepGen Inc.

FDA issued clinical hold for IND to initiate CONNECT2-EDO51 Phase 2 study of PGN-EDO51 in DMD patients.
FDA to provide official clinical hold letter within 30 days; CONNECT2 remains open in the UK.
Open-label CONNECT1-EDO51 study in Canada continues; 10 mg/kg cohort now fully enrolled.
PepGen intends to work closely with FDA to address questions expeditiously.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.